Is Revvity (RVTY) a risky stock?
As of July 21, 2026, Clavix grades Revvity (RVTY) B for risk, a composite score of 70 out of 100 on an A+ to F scale, which puts RVTY in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind RVTY's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how RVTY scores on each, as of July 21, 2026.
What's moving RVTY's risk right now
Company-specific signals Clavix flags behind RVTY's current grade, drawn from recent news and filings as of July 21, 2026.
An rating piece asks whether Revvity's Claude integration validates its AI data strategy and could lift Signals Software's position in life sciences AI. Separately, Revvity's 2026 Impact Report added an initial Scope 3 greenhouse-gas disclosure.
Revvity will release its second-quarter 2026 financial results before the market opens on Tuesday, August 4, 2026, and then host a conference call. The date itself sets the next clear catalyst for the stock.
Revvity is offering its Signals Software to emerging biotech companies so they build on its platform from day one. The move aims to seed a longer-term customer pipeline for Revvity's software segment before those startups scale up.
What a B grade means
On the Clavix A+ to F scale, RVTY's composite of 70 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell RVTY or any security. Grades are risk indicators, not predictions of return. Data may be delayed.